Roche extends the tender offer for Spark Therapeutics, Inc.’s shares

By Akshay Kedari  | Date: 2019-08-01

Roche extends the tender offer for Spark Therapeutics, Inc.’s shares

The extended tender would provide additional time for the U.S. FTC and U.K. CMA to complete their prior disclosed evaluations of Roche’s acquisition of Spark. 

Swiss healthcare giant, Roche Holding AG have recently announced that it has stretched the offering period of its formerly announced tender offer to purchase all the outstanding shares of common stock of U.S. pharmaceutical company, Spark Therapeutics, Inc. for a reasonable price of $114.50 per share.

According to reliable sources, Citibank, N.A., the depository for the offer, had advised Roche that, as of July 30th, around 9,715,086 shares of Spark had been validly tendered and received, leaving an estimated 25.2% of Spark’s shares as outstanding.

Stockholders who have already given their shares of Spark, do not have to re-tender their shares or take any other action as a result of the extension, suggest reports.

Moreover, closing of the tender offer would depend upon customary closing conditions, including the termination of the valid waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. Meanwhile, MacKenzie Partners, Inc., information agent for the offer would request for documents, while questions regarding the offer would be diverted to the company.

For the record, Spark Therapeutics is a startup pharmaceutical company that is focused on developing, discovering and delivering gene therapies. The company aims on developing medicines for genetic diseases, including blindness, lysosomal storage disorders, haemophilia and neurodegenerative diseases.

As for Roche, it is focused on progressing science to improve people’s health. The availability of diagnostics and pharmaceuticals under one roof has helped Roche become a leader in personalized healthcare. The company is also a frontrunner in diabetes management and a global leader in vitro diagnostics and tissue-based cancer diagnostics.

Headquartered in Basel, Switzerland, the Roche Group is spread over 100 countries with a workforce of about 94,000 employees recorded last year. Additionally, in 2018, Roche invested a total of CHF 11 billion in R&D and managed to record a sale of CHF $56.8 billion, cite sources.

Source Credit: https://www.globenewswire.com/news-release/2019/07/31/1894176/0/en/Roche-and-Spark-Therapeutics-Inc-announce-extension-of-tender-offer-for-shares-of-Spark-Therapeutics-Inc.html

 

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Amazon Smart Commerce to digitize 10 million small businesses in India

Amazon Smart Commerce to digitize 10 million small businesses in India

By Akshay Kedari

E-commerce behemoth Amazon Inc. has reportedly launched a “Smart Commerce” initiative in India, aiming to digitalize 10 million small businesses, allow for USD 10 billion worth in exports, and create 2 million jobs by 2025. During the ...

McDonald’s to leave Russia after 30 years amidst Ukraine’s invasion

McDonald’s to leave Russia after 30 years amidst Ukraine’s invasion

By Akshay Kedari

After Ukraine’s invasion, multinational fast-food giant McDonald's Corp. is reportedly planning to sell all its restaurants in Russia, pulling operations from the nation after 30 years. The world's biggest fast-food chain closed 847 ...

Berlin’s GetHenry bags USD 17.4 Mn seed funding for business expansion

Berlin’s GetHenry bags USD 17.4 Mn seed funding for business expansion

By Akshay Kedari

GetHenry, a Berlin-based company that offers couriers and logistics organizations electric last-mile delivery bikes, has reportedly raised USD 17.4 million seed round to grow its operations across Europe. The latest investment round was led by LocalG...

Ferrari to equip the upcoming Purosangue with its trademark V12 engine

Ferrari to equip the upcoming Purosangue with its trademark V12 engine

By Akshay Kedari

Italian luxury sports car manufacturer Ferrari S.p.A. will equip its much-awaited Purosangue SUV with a 12-cylinder engine, as it focused more on fuel-efficient models. Confirming the news, Ferrari Chief Executive Benedetto Vigna claimed that the com...

White House to spend USD 3 billion on EV battery manufacturing in U.S.

White House to spend USD 3 billion on EV battery manufacturing in U.S.

By Akshay Kedari

According to reliable sources, the Biden administration is planning to provide USD 3 billion in finance to reinforce EV battery manufacturing capabilities in the United States. The apparent funds will be issued by the Department of Energy from Presid...